Your browser doesn't support javascript.
loading
Memory impairment in the D2.mdx mouse model of Duchenne muscular dystrophy is prevented by the adiponectin receptor agonist ALY688.
Bellissimo, Catherine A; Castellani, Laura N; Finch, Michael S; Murugathasan, Mayoorey; Gandhi, Shivam; Sweeney, Gary; Abdul-Sater, Ali A; MacPherson, Rebecca E K; Perry, Christopher G R.
Afiliação
  • Bellissimo CA; School of Kinesiology & Health Science, York University, Toronto, ON, Canada.
  • Castellani LN; Muscle Health Research Centre, York University, Toronto, Canada.
  • Finch MS; School of Kinesiology & Health Science, York University, Toronto, ON, Canada.
  • Murugathasan M; Muscle Health Research Centre, York University, Toronto, Canada.
  • Gandhi S; Department of Health Sciences, Brock University, St Catharines, ON, Canada.
  • Sweeney G; School of Kinesiology & Health Science, York University, Toronto, ON, Canada.
  • Abdul-Sater AA; Muscle Health Research Centre, York University, Toronto, Canada.
  • MacPherson REK; School of Kinesiology & Health Science, York University, Toronto, ON, Canada.
  • Perry CGR; Muscle Health Research Centre, York University, Toronto, Canada.
Exp Physiol ; 108(9): 1108-1117, 2023 09.
Article em En | MEDLINE | ID: mdl-37415288
NEW FINDINGS: What is the central question of this study? Can adiponectin receptor agonism improve recognition memory in a mouse model of Duchenne muscular dystrophy? What is the main finding and its importance? Short-term treatment with the new adiponectin receptor agonist ALY688 improves recognition memory in D2.mdx mice. This finding suggests that further investigation into adiponectin receptor agonism is warranted, given that there remains an unmet need for clinical approaches to treat this cognitive dysfunction in people with Duchenne muscular dystrophy. ABSTRACT: Memory impairments have been well documented in people with Duchenne muscular dystrophy (DMD). However, the underlying mechanisms are poorly understood, and there is an unmet need to develop new therapies to treat this condition. Using a novel object recognition test, we show that recognition memory impairments in D2.mdx mice are completely prevented by daily treatment with the new adiponectin receptor agonist ALY688 from day 7 to 28 of age. In comparison to age-matched wild-type mice, untreated D2.mdx mice demonstrated lower hippocampal mitochondrial respiration (carbohydrate substrate), greater serum interleukin-6 cytokine content and greater hippocampal total tau and Raptor protein contents. Each of these measures was partly or fully preserved after treatment with ALY688. Collectively, these results indicate that adiponectin receptor agonism improves recognition memory in young D2.mdx mice.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Distrofia Muscular de Duchenne Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: Exp Physiol Assunto da revista: FISIOLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Canadá País de publicação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Distrofia Muscular de Duchenne Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: Exp Physiol Assunto da revista: FISIOLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Canadá País de publicação: Reino Unido